|1.||Priebe, Waldemar: 9 articles (04/2015 - 12/2007)|
|2.||Heimberger, Amy B: 5 articles (12/2014 - 09/2008)|
|3.||Kong, Ling-Yuan: 4 articles (12/2014 - 09/2008)|
|4.||Wei, Jun: 4 articles (12/2014 - 09/2008)|
|5.||Zhou, Xuan: 4 articles (05/2014 - 09/2013)|
|6.||Zhang, Lun: 4 articles (05/2014 - 09/2013)|
|7.||Fuller, Gregory N: 3 articles (12/2014 - 09/2008)|
|8.||Wang, Xudong: 3 articles (05/2014 - 01/2014)|
|9.||Liu, Aiqin: 3 articles (05/2014 - 01/2014)|
|10.||Lu, Kang: 2 articles (08/2015 - 04/2015)|
01/01/2011 - "The STAT3 inhibitor, WP1066, has displayed marked efficacy with minimal toxicity against malignancy in murine models, including established intracerebral tumors. "
04/30/2015 - "WP1066 inhibited Stat3 activation in tumor-associated endothelial cells, reducing their infiltration and angiogenesis. "
05/01/2014 - "TSCCA and TCA8113 showed reduction in tumor cell proliferation, invasion ability and miR-21 expression by WP1066 treatment. "
01/01/2013 - "Treatment of Stat3 inhibitor WP1066 in B16-F10 tumor cells inoculated wild-type mice inhibits tumor growth. "
01/01/2009 - "In vivo testing of WP1066 in a nude mouse orthotopic model of HNSCC demonstrated significant anti-tumor effects, with histological evidence of decreased cellular proliferation and angiogenesis. "
|2.||Melanoma (Melanoma, Malignant)
09/15/2008 - "The antitumor cytotoxic effects of WP1066 and its ability to induce antitumor immune responses suggest that this compound has potential for the effective treatment of melanoma metastatic to brain."
08/01/2013 - "Furthermore, treatment with the Stat3 inhibitor, WP1066, resulted in growth inhibition in both vemurafenib-sensitive and -resistant melanoma cells. "
07/01/2012 - "However, in mice with intracerebral melanoma, the greatest therapeutic benefit was seen in animals treated with cytotoxic CTX dosing and WP1066, whose median survival time was 120 days, an increase of 375%, with 57% long-term survivors. "
07/01/2012 - "Combinational therapy of WP1066, with both metronomic and cytotoxic dosing of CTX, was investigated in a model system of systemic and intracerebral melanoma in syngeneic mice. "
07/01/2009 - "These results suggest that WP1066 enhances T cell cytotoxicity against melanoma through inhibition of Tregs."
|3.||Neoplasm Metastasis (Metastasis)
04/30/2015 - "Furthermore, inhibition of Stat3 by WP1066 decreased the incidence of brain metastases and increased survival in a preclinical model of breast cancer brain metastasis. "
04/30/2015 - "Our results indicate that WP1066 can inhibit tumor angiogenesis and brain metastasis mediated by Stat3 in endothelial and tumor cells. "
07/01/2009 - "We hypothesized that WP1066, a novel inhibitor of STAT3 signaling, reverses immune suppression through the inhibition of Tregs and that this contributes to the antitumor activity of this agent against melanoma brain metastases. "
09/15/2008 - "We hypothesized that WP1066, a novel STAT3 blockade agent, has marked antitumor activity, even against the melanoma metastasis to brain, a site typically refractory to therapies. "
10/02/2014 - "JAK2 peaked on postoperative day 14 while phosphorylated STAT3 peaked on postoperative day 7 and gradually decreased thereafter and SOCS3׳s peak level on postoperative day 3. When WP1066 were administered intrathecally, the pain behaviors of the bCCI rats were significantly improved (P<0.05). "
10/02/2014 - "WP1066, which inhibited the STAT3 pathway specifically, could partially alleviate the pain behavior of the bCCI rats. "
|5.||Neuralgia (Stump Neuralgia)
10/02/2014 - "STAT3 inhibitor WP1066 as a novel therapeutic agent for bCCI neuropathic pain rats."
10/02/2014 - "To evaluate the contribution of the JAK2/STAT3 pathway to neuropathic pain and the potentiality of this pathway as a novel therapeutic target, we examined the effects of the STAT3 inhibitor WP1066 by intrathecal administration in a rat model of bilateral chronic constriction injury (bCCI). "
10/02/2014 - "To observe the influence of WP1066 on neuropathic pain and its molecular mechanism, WP1066 (10 μl, 10 mmol/L in DMSO) or the same capacity of DMSO as the control were applied through the intrathecal tube on the day before bCCI surgery, and on the postoperative day 3 and 5. Behavioral tests were performed to observe the therapeutic effect on mechanical, thermal and cold hyperalgesia. "
|2.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|3.||Small Interfering RNA (siRNA)
|5.||Dimethyl Sulfoxide (DMSO)
|7.||alpha- cyano- (3,4- dihydroxy)- N- benzylcinnamide
|8.||Histone Deacetylase Inhibitors
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|10.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|1.||Heterologous Transplantation (Xenotransplantation)